Study identifier:M/34273/47
ClinicalTrials.gov identifier:NCT02153489
EudraCT identifier:2013-003373-10
CTIS identifier:N/A
A pilot, double-blind, placebo-controlled, 2-period crossover study to assess the effect of aclidinium bromide 400 μg bid on COPD symptoms and sleep quality after 3 weeks of treatment in patients with stable moderate-to-severe chronic obstructive pulmonary disease (COPD)
Chronic obstructive pulmonary disease (COPD)
Phase 4
No
Aclidinium bromide, Placebo
All
30
Interventional
40 Years +
Allocation: Randomized
Endpoint Classification: Safety/Efficacy
Intervention Model: Crossover Assignment
Masking: Double Blind
Primary Purpose: Treatment
Verified 01 Sept 2016 by AstraZeneca
AstraZeneca
-
No locations available
Arms | Assigned Interventions |
---|---|
Experimental: Aclidinium bromide Aclidinium bromide 400 μg administered via oral inhalation (Genuair® dry powder inhaler) one inhalation twice daily (12 hours apart, morning and evening). | - |
Placebo Comparator: Placebo Placebo administered via oral inhalation (Genuair® dry powder inhaler) one inhalation twice daily (12 hours apart, morning and evening). | - |